Stay updated on Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The record describes a Phase I/II study of HER2-BAT cells with pembrolizumab for metastatic breast cancer, including its treatment schedules, eligibility criteria, and outcome measures. It also provides study status and enrollment details, contact and investigator information, and study documents.
    Difference
    53%
    Check dated 2026-11-09T13:48:25.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.2 to v3.8.0, while the page content remains a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-02T13:53:31.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    A banner announces NIH’s terminology transition from “Artificial Intelligence” to “Super Intelligence” under Executive Order 14434 and links to updates and FAQs.
    Difference
    1%
    Check dated 2026-10-26T14:50:38.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.1 to v3.7.2 while the page continued to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-19T14:44:32.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    The footer’s revision label changed from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-12T15:53:56.000Z thumbnail image
  6. Check
    52 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the study content with an access-denied page. Previously visible study details and navigation are no longer accessible.
    Difference
    19%
    Check dated 2026-09-21T22:05:25.000Z thumbnail image

Stay in the know with updates to Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial page.